Ginkgo Bioworks (DNA) completed the first milestone of a partnership with Merck (MRK) focused on improving biologic manufacturing. As part of ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago.

Ginkgo Bioworks Holdings, Inc. (DNA) revealed Loss for third quarter that decreased from last year The company's earnings totaled ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...

BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of ...

Ginkgo Bioworks has been busy, announcing not just one but three acquisitions and the creation of a network backed by 25 partners that will offer ‘end-to-end’ services to R&D clients.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) ...

Ginkgo Bioworks Holdings Inc, based in Boston, Massachusetts, specializes in cell programming to revolutionize the production of various products. By manipulating cells, they create novel ...

BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading ...

Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. On average, sell-side analysts expect that Ginkgo Bioworks Holdings, Inc. will post -12.6 earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...